Article

Early treatment of UTI in infants may not prevent renal scarring

Early and appropriate treatment of urinary tract infection, especially during the first 24 hours after the onset of symptoms, diminishes the likelihood of renal involvement during the acute phase of the infection, but does not prevent scar formation, researchers reported in Pediatrics (2007; 120:e922-e928).

Early and appropriate treatment of urinary tract infection, especially during the first 24 hours after the onset of symptoms, diminishes the likelihood of renal involvement during the acute phase of the infection, but does not prevent scar formation, researchers reported in Pediatrics (2007; 120:e922-e928).

In a prospective clinical study, pediatricians from the University of Athens and Children’s Hospital, Athens, Greece, evaluated whether the time interval between the onset of the renal infection and the start of therapy correlates with the development of acute inflammatory changes and the subsequent development of renal scars. A total of 278 infants (153 male and 125 female) age 0.5 to 12 months with their first urinary tract infection were enrolled in the study.

The median time between the onset of infection and the institution of therapy was 2 days. Renal inflammatory changes were documented in 57% of the infants. Renal defects were recorded in 41% of the patients treated within the first 24 hours since the onset of fever versus 75% of those treated on day 4 and onward. Renal scarring was developed in 51% of the infants with an abnormal scan in the acute phase of infection.

The frequency of scarring in infants treated early and in those whose treatment was delayed did not differ, suggesting that once acute pyelonephritis has occurred, ultimate renal scarring is independent of the timing of therapy. Acute inflammatory changes and subsequent scarring were more frequent in the presence of vesicoureteral reflux, especially high-grade VUR. However, the difference was not significant, which suggests that renal damage may be independent of the presence of VUR.

Related Videos
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Ravi Munver, MD, answers a question during a Zoom video interview
Interpreting ART toxicity and tolerability for bladder cancer, with Vedang Murthy, MD
1 KOL is featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.